NDA 208078 · Catalyst Pharms
Firdapse
Amifampridine Phosphate · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 28, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
15
8 Phase 3, 0 recruiting
FAERS reports
2,964
1,591 serious, 216 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 16, 2026.
FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. ( 1 )
Mechanism: The mechanism by which amifampridine exerts its therapeutic effect in LEMS patients has not been fully elucidated. Amifampridine is a broad-spectrum potassium channel blocker.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 2024 Supplement 12 · Efficacy OrphanLetterLabel
- Sep 29, 2022 Supplement 8 · Efficacy · priority review OrphanLetterLabel
- Nov 28, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- FIRDAPSE · AMIFAMPRIDINE PHOSPHATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amifampridine" as an intervention, any sponsor and status, largest first.
- Efficacy of 3,4-DAP in Fatigue Associated With Multiple SclerosisPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00190268 · 126 participants · Start Feb 2005 · Primary completion Jun 2008
Drug: 3,4-diaminopyridine · For: Multiple Sclerosis
Sites: Créteil, France; Paris, France; Rennes, France · 4 sites in all
- Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic StimulationPivotal-lookingCompleted
University of AarhusAcademic, hospital or other
NCT00342381 · 120 participants (planned) · Start Jun 2006
Drug: 3,4-diaminopyridine; Placebo · For: Multiple Sclerosis; Fatigue
Sites: Aarhus, Denmark
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGPivotal-lookingCompleted
Catalyst Pharmaceuticals, Inc.Industry
NCT03304054 · 93 participants · Start Apr 18, 2018 · Primary completion Jan 31, 2020
Drug: Amifampridine Phosphate; Placebo Oral Tablet · For: Myasthenia Gravis, Generalized
Sites: Cleveland, Ohio; Philadelphia, Pennsylvania
- Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)Pivotal-lookingTerminated
Catalyst Pharmaceuticals, Inc.Industry
NCT03579966 · 63 participants · Start Jun 11, 2018 · Primary completion Aug 5, 2022
Drug: Amifampridine Phosphate · For: Myasthenia Gravis, MuSK; AChR Myasthenia Gravis
Sites: Cleveland, Ohio; Philadelphia, Pennsylvania; Milan, Italy
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Pivotal-lookingCompleted
Catalyst Pharmaceuticals, Inc.Industry
NCT01377922 · 38 participants · Start Jun 2011 · Primary completion Jul 2016
Drug: Amifampridine Phosphate; Placebo · For: Lambert Eaton Myasthenic Syndrome
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 14 sites in all
Jacobus PharmaceuticalIndustry
NCT01511978 · 32 participants · Start Jan 2012 · Primary completion Feb 2014
Drug: Continuous 3,4-DAP; Taper 3,4-DAP to Placebo · For: Lambert-Eaton Myasthenic Syndrome; Eaton-Lambert Myasthenic Syndrome
Sites: Sacramento, California; Indianapolis, Indiana; Durham, North Carolina · 7 sites in all
FDA Office of Orphan Products DevelopmentFederal agency
NCT00004832 · 26 participants · Start Aug 1994
Drug: 3,4-diaminopyridine · For: Lambert-Eaton Myasthenic Syndrome
- Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)Pivotal-lookingCompleted
Catalyst Pharmaceuticals, Inc.Industry
NCT02970162 · 26 participants · Start Nov 2016 · Primary completion Oct 2017
Drug: Amifampridine Phosphate; Placebo Oral Tablet · For: Lambert-Eaton Myasthenic Syndrome
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthenia379
- drug ineffective357
- paraesthesia347
- paraesthesia oral281
- fall258
- condition aggravated223
- fatigue217
- nausea210
- muscular weakness204
- headache191
- diarrhoea177
- dizziness175
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 379 |
| 2020 | 253 |
| 2021 | 273 |
| 2022 | 171 |
| 2023 | 368 |
| 2024 | 289 |
| 2025 | 537 |
| 2026 | 681 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Firdapse (Amifampridine Phosphate)
2024 spending
$178M
Beneficiaries
402
3,824 claims
Per beneficiary
$442,345
$238.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $79,392,496 |
| 2021 | $92,703,276 |
| 2022 | $126,614,542 |
| 2023 | $146,333,212 |
| 2024 | $177,822,831 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The use of aminopyridines in neurological disorders.
Sedehizadeh S, Keogh M, Maddison P · Clin Neuropharmacol 2012 · Systematic Review
- Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
Remijn-Nelissen L, Bakker WR, van Gelder T, et al. · Neurology 2026 · Randomized Controlled Trial
- Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. · Muscle Nerve 2016 · Clinical Trial, Phase III, Multicenter Study
- Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).
Hatanaka Y, Mori-Yoshimura M, Utsugisawa K, et al. · Intern Med 2025 · Multicenter Study, Clinical Trial, Phase III
- Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial.
Bonanno S, Giossi R, Zanin R, et al. · J Neurol 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Sanders DB, Juel VC, Harati Y, et al. · Muscle Nerve 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Catalyst Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.